Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Author(s) -
Shuaijian Ni,
Zhenjian Zhuo,
Yufei Pan,
Liang Yu,
Fangfei Li,
Jin Liu,
Luyao Wang,
Xiaoqiu Wu,
Dijie Li,
Youyang Wan,
Lihe Zhang,
Zhenjun Yang,
BaoTing Zhang,
Aiping Lü,
Ge Zhang
Publication year - 2020
Publication title -
acs applied materials and interfaces
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.535
H-Index - 228
eISSN - 1944-8252
pISSN - 1944-8244
DOI - 10.1021/acsami.0c05750
Subject(s) - aptamer , immunogenicity , nanotechnology , oligonucleotide , computational biology , biochemical engineering , computer science , materials science , biology , microbiology and biotechnology , engineering , immunology , dna , antibody , genetics
Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom